Home

WILLIAM J FEDERICI

CIK 1260426 · Sr. VP & CFO · last filed 2026-06-26

WILLIAM J FEDERICI is a Sr. VP & CFO who has filed 134 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing, for STVN, was dated Jun 26, 2026. Across all open-market trades the lifetime net is −$23.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $98.5M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$98.46M

Companies

5

Total Filings

134

Lifetime Open-Market Net

-$23.17M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
STVN Director 58,580 $19.75 $1.16M -$25.5K 1 2026-06-26
Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted Director 47,824 $1.30 $62.2K -$80 17 2023-10-11
WST Sr. VP & CFO 271,727 $357.50 $97.14M -$23.14M 100 2018-06-11
PATH Director 13,500 $11.76 $158.8K $0 14 2014-01-03
Synvista Therapeutics, Inc. (SYI) Delisted Director — — — $0 1 2008-10-10

Recent Filings

134 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-26 STVN Mixed +3,482 -$25.5K EDGAR
2023-10-11 Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted Mixed −75,778 $0 EDGAR
2023-06-15 Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted Mixed +47,709 -$40 EDGAR
2022-06-16 Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted Mixed +23,069 -$40 EDGAR
2021-08-05 Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted Grant (A) +5,000 $0 EDGAR
2020-06-11 Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted Grant (A) — $0 EDGAR
2019-06-13 Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted Grant (A) — $0 EDGAR
2018-10-02 Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted Grant (A) — $0 EDGAR
2018-07-03 Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted Grant (A) — $0 EDGAR
2018-06-11 WST Mixed +32,793 -$2.50M EDGAR
Showing 1–10 of 134
Page 1 of 14
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.